Olinvacimab Antibody is a research-grade biosimilar monoclonal antibody targeting CD309. It is a humanized IgG1-kappa-lambda antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
Vascular endothelial growth factor receptor 2 (CD309/VEGFR-2) is a ~151 kDa protein. Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. CD309 is the therapeutic target of ramucirumab (Cyramza).
Product Name:
Olinvacimab Antibody
SKU:
GXBS00274
Size:
100 µg, 1 mg
Antibody Type:
Monoclonal Antibody
Target:
CD309
Isotype:
IgG1-kappa-lambda
Host Species:
Human
Reactivity:
Human
Applications:
ELISA, FCM, Functional assay, Research in vivo
Synonyms:
SSS-23, TTAC-0001, tanibirumab, 2095504-49-5
Purity:
>95% as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
Formulation:
0.01M PBS pH 7.4.
State of Matter:
Liquid
Regulatory Status:
For research use only. Not suitable for clinical or therapeutic use.
Product Preparation:
Protein A/G purified from cell culture supernatant.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
